The Global Health Body Issues Warning Over Acute Scarcity of Weight-Loss Injections

Less than a tenth of patients eligible to benefit from GLP-1 drugs like Wegovy are able to get them, states the WHO as it issues its inaugural recommendations on the medications.

Considering over a billion people worldwide now living with obesity, it is advocating for broader and more equitable access to this class of drugs.

Per projections, over two billion will be obese by 2030 without intervention.

"The new guidance acknowledges that obesity is a lifelong illness that can be managed with thorough and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and logistical bottlenecks are key hurdles to broad access to the treatments that can help people shift considerable body mass, explains the organization.

Skinny Jab Shortage

Even under the current most favorable outlook, the manufacturing of such drugs could only cover around 100 million people – fewer than 10% of those who need them, according to the health organization.

The guideline urges nations and manufacturers to widen availability, via measures including voluntary licensing.

Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026.

How Obesity Drugs Work

GLP-1 drugs mimick a biological compound to reduce digestion speed, reduce hunger and boost satiety so individuals eat less.

Individuals commonly begin shedding pounds in the initial weeks of beginning the once-weekly jabs.

Research suggests users may see weight return after a year of discontinuing the drug, because their normal hunger resume.

To be carrying excess weight elevates your risk for contracting medical conditions, such as type 2 diabetes, heart disease, brain attack, and certain cancers.

Excess weight impacts individuals in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, as per the WHO.